What's Happening?
AstraZeneca and HUTCHMED have reported positive high-level results from the SAFFRON Phase III trial, demonstrating that TAGRISSO (osimertinib) combined with savolitinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients
with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This trial focused on patients whose tumors exhibited high levels of MET overexpression or amplification and had progressed after prior treatment with TAGRISSO. MET-driven resistance is a common mechanism of progression in EGFRm NSCLC patients treated with third-generation EGFR-tyrosine kinase inhibitors (TKIs), often leading to poor prognosis and a lack of effective, well-tolerated treatment options. The safety profile of the combination therapy was consistent with the known profiles of each medicine, with no new safety findings observed. These findings reinforce TAGRISSO as a foundational therapy in EGFRm lung cancer and highlight the potential of this novel combination to address MET-driven resistance.
Why It's Important?
This clinical trial represents a significant advancement in the treatment of EGFRm NSCLC, particularly for patients who develop MET-driven resistance to existing therapies. Approximately one in three patients treated with third-generation EGFR-TKIs experience MET overexpression or amplification, which is associated with poor outcomes. The SAFFRON trial's success in demonstrating improved PFS and OS with the TAGRISSO plus savolitinib combination addresses a critical unmet medical need for this patient population. By providing a biomarker-directed, all-oral treatment option, this combination could offer a new standard of care, improving both the duration and quality of life for patients. The results also underscore the importance of MET testing to guide treatment decisions, enabling clinicians to identify patients who would benefit most from this targeted therapy. This development further solidifies AstraZeneca's leadership in EGFR-mutated lung cancer and reinforces the strategy of developing novel combinations to improve patient outcomes across various stages and lines of therapy.
What's Next?
The positive data from the SAFFRON Phase III trial will be presented at a forthcoming medical meeting and subsequently shared with global regulatory authorities. This step is crucial for seeking regulatory approvals in various regions, including the US, to make this combination therapy available to a wider patient population. TAGRISSO plus savolitinib is already approved in China for patients with locally advanced or metastatic EGFRm NSCLC with MET amplification after disease progression on EGFR-TKI therapy, based on the SACHI Phase III trial. The combination also received temporary authorization in Switzerland. The companies will work towards securing similar approvals globally. Further research and development efforts will likely continue to explore the optimal integration of this combination into existing treatment paradigms and to identify additional patient subgroups who could benefit. The emphasis on MET testing suggests a future where precision medicine plays an even more central role in guiding lung cancer treatment strategies.
Beyond the Headlines
The success of the TAGRISSO plus savolitinib combination reflects a broader trend in oncology towards personalized medicine and combination therapies that target multiple resistance mechanisms. As cancer treatments become more sophisticated, understanding the molecular drivers of resistance, such as MET amplification, is crucial for developing effective strategies. This trial's outcome highlights the value of collaborative research between pharmaceutical companies like AstraZeneca and HUTCHMED in bringing innovative treatments to patients. Furthermore, the focus on an all-oral option for a complex cancer type can significantly improve patient convenience and adherence, potentially leading to better real-world outcomes. The ongoing development of targeted therapies and the emphasis on biomarker testing are transforming the landscape of cancer care, moving towards more tailored and effective treatments that can overcome the challenges of tumor evolution and drug resistance.
